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ABSTRACT 
To examine the role of iron in mediating hepatocellular damage during reperfusion after 
hemorrhagic shock, we studied five groups of n=4 or 5 dogs, bled to reduce mean 
arterial pressure to 35 mmHg (± 5mrnHg) for three hours and subsequently treated 20 
minutes prior to reinfusion of shed blood with either 0.9% saline, 5 ml/kg; deferoxam­
ine, 50 µg/kg in 0.9% saline; 6% pentastarch solution, 5 ml/kg; deferoxamine covalently 
bound to 6% pentastarch, 50 µg/kg; or iron loaded deferoxamine in 0.9% saline. 
Saturation of iron binding capacity increased during hemorrhagic shock and remained 
high in all but the def eroxamine pentastarch treated group. Serum iron levels were 
significantly lower in animals treated with saline or iron loaded deferoxamine. Serum 
alanine aminotransferase (ALT), a specific marker for hepatocellular injury in the dog, 
was measured as an indicator of hepatic reperfusion injury. During shock, ALT did not 
change significantly from the normal in any group. After reperfusion, however, ALT 
rose sharply in animals reperfused without iron chelators, from a mean baseline value of 
less than 36 U /L to a post-reperfusion plateau of 5509 ± 2260 U /L at four hours, a pat­
tern suggesting hepatic reperfusion injury. Iron loaded deferoxamine control dogs, also 
showed a substantial rise in ALT activity to 6287 ± 2134 U/L four hours after reperfu­
sion. However, dogs treated with free deferoxamine showed significantly smaller eleva­
tions in ALT to only 655 ± 139 U /L (P <0.05). Histologic evaluation of liver sections 
showed significantly smaller areas of necrosis in both of the deferoxamine treated groups 
compared to other groups. These findings suggest that deferoxamine preventable reper­
fusion injury of the liver, perhaps involving the iron catalyzed Haber-Weiss reaction, 
may play a role in the pathophysiology of hemorrhagic shock. 
Keywords : iron chelators, lipid peroxidation, liver, oxidative stress, reperfu­
sion injury 























